Table 1. Characteristics of the included studies.
| First author | Year | Country | No. of Patients (CXCR4 High/Low) | Age (y) | Follow-up (m) | Histological type | FIGO stage | Chemotherapy regimens (n) | Residual tumor | Antibody | Subcellular localization | Cut-off | Survival | Analysis | NOS Score |
| Li | 2013 | China | 124(75/49) | >55 y 53, ≤55 y 71 | NA | S 52, M 38, E 15, U 19 | I–II 31, III–IV 93 | platinum-based chemotherapy 124 | NA | Sigma | NA | Low 0–4; High 5–12 (IRS) | OS/PFS | Multi | 7 |
| Sekiya | 2012 | Japan | 48(24/24) | 52(27–69) | 63.8(4.3–204.3) | C 48 | I 24, II–IV 18 Unknown 6 | platinum-based chemotherapy 37 | Absent 38, Present 4 | Chemicon | NA | Low 0–3; High 4–6 (IRS) | OS/PFS | Multi | 9 |
| Popple | 2012 | UK | 241(214/27) | < 30 y 1, 30 y-60 y 92, >60 y 146 | 167.0(95.0–335.0) | S 128, E 30, M 33, C 18, U 31 O 11 | I–II 89, III–IV 144, Unknown 8 | Adjuvant therapy: Yes 168; No, 67 | Absent 143, Present 201 | R&D | Cytoplasm and nucleus (mainly nucleus) | Low 0–60; high 60–300 (H-score) | OS | Multi | 8 |
| Pils-cyt | 2007 | Austria | 119(64/55) | 58.6(27.6–87.2) | 43.7(0.4–168.7) | S 65, E 23, M 6, C 6, U 12, Mixed 7 | I–II 43, III–IV 76 | CBP+PTX 81; CDDP+CTX 9 | NA | R&D | Cytoplasm | Low 0–1; High 2–3 | OS | Multi | 8 |
| Pils-nuc | 2007 | Austria | 101(22/79) | 59.2(47.1–71.3) | 43.7(0.4–168.7) | S 55, E 20, M 6, C 5, U 11, Mixed 4 | I–II 36, III–IV 65 | CBP+PTX 81; CDDP+CTX 9 | NA | R&D | nucleus | Low, no visible staining; High, visible staining | OS | Multi | 8 |
| Oda | 2007 | Japan | 52(20/32) | 58(36–77) | 26.1(1.0–61.8) | S 49, E 4 | I–II 7, III–IV 46 | PTX+CBP 50; DOC+CBP 2 | <2 cm 36, >2 cm 11 | BD | NA | Low 0–1+ staining with <10% positive cells; High 2–3+ staining with >10% positive cells (IRS) | OS | Multi | 6 |
| Jiang | 2006 | China | 44(26/18) | 51(43–60) | 37.0(7.0–70.0) | S 34, E 8, M 1, C 1 | I–II 11, III–IV 33 | CDDP+CTX 44 | <1 cm 28, >1 cm 16 | R&D | Cytoplasm and nucleus (mainly cytoplasm) | Low 0; High 1–12 (IRS) | OS/PFS | Multi | 7 |
C, clear cell; S, serous; E, endometrioid; M, mucinous; U, Undifferentiated; O Others; NA, not available; FIGO, International Federation of Gynecology and Obstetrics; IRS, immunohistochemical score; OS, overall survival; PFS, progression-free survival; cyt, cytoplasm; nuc, nuclear; HR, Hazard Ratio; RR, Risk Ratio; Multi, multivariate analysis; NOS, Newcastle-Ottawa Scale; CDDP, Cisplatin; PTX, paclitaxel; CBP, carboplatin; CTX, cyclophosphamide; DOC, docetaxel.